November 02, 2009
http://www.associatedcontent.com/
Keyword: Dr. Timothy Stemmler, Wayne State University, University of Michigan-Dearborn, iron deficiency, Anemia, Parkinson's, Fredreich's Ataxia, frataxin.
Monday, November 2, 2009
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers
PR-inside.com,
London, November , 02, 2009
Keywords: H. Lundbeck A/S, phase IIa clinical studies, project Lu AA24493, safety and
tolerability, Friedreich's ataxia, carbamoylated form of human erythropoietin (EPO), loss of haematopoietic effects, neuronal damage,
----------------------------------------------------------
Pharmacy Europe,
Latest News, Monday 2nd November 2009
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO)
---------------------------------------------------------
Reuters.com
Mon Nov 2, 2009 5:10am EST
Lundbeck says expands stroke drug candidate trials
London, November , 02, 2009
Keywords: H. Lundbeck A/S, phase IIa clinical studies, project Lu AA24493, safety and
tolerability, Friedreich's ataxia, carbamoylated form of human erythropoietin (EPO), loss of haematopoietic effects, neuronal damage,
----------------------------------------------------------
Pharmacy Europe,
Latest News, Monday 2nd November 2009
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO)
---------------------------------------------------------
Reuters.com
Mon Nov 2, 2009 5:10am EST
Lundbeck says expands stroke drug candidate trials
Subscribe to:
Posts (Atom)